Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

13.24EUR
21 Sep 2018
Change (% chg)

€-0.11 (-0.82%)
Prev Close
€13.35
Open
€13.45
Day's High
€13.65
Day's Low
€13.24
Volume
584,396
Avg. Vol
178,710
52-wk High
€19.42
52-wk Low
€10.25

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.27
Market Cap(Mil.): €287.57
Shares Outstanding(Mil.): 22.30
Dividend: --
Yield (%): --

Financials

  MDG1k.DE Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.81 -- --
ROI: -15.86 1.79 14.61
ROE: -18.62 3.28 16.33

BRIEF -Medigene Raises 2018 Guidance After H1 Results

* NOW EXPECTS TO GENERATE TOTAL 2018 REVENUE OF BETWEEN EUR 9.5 - 10.5 MILLION

07 Aug 2018

German stocks - Factors to watch on May 15

BERLIN/FRANKFURT, May 15 The following are some of the factors that may move German stocks on Tuesday:

15 May 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

14 May 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

14 May 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

14 May 2018

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

11 Apr 2018

Earnings vs. Estimates